Effects of psychotropics on glycosylated hemoglobin (HbA1c) in a cohort of bipolar patients

Bipolar Disorders

Volumn 9, Issue 7, 2007, Pages 772-778

  Castilla Puentes, Ruby ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE   (United States)

Author keywords

Bipolar disorder; HbA1c; Hyperglycemia; Psychotropics

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOZAPINE; FLUPHENAZINE; GABAPENTIN; HEMOGLOBIN A1C; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENYTOIN; PROCHLORPERAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG SAFETY; FEMALE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; RISK FACTORS; SEX FACTORS;

EID: 35748952196     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2007.00534.x     Document Type: Article

References (19)

1. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacol 2003; 166: 315-332.
2. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effect of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865.
3. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003; 25: 1150-1171.
4. Schwenkreis P, Assion HJ. Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 2004; 5: 73-82.
5. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database. J Clin Psychopharmacol 2003; 23: 328-335.
6. Koro CE, Fedder DO, L'Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population-based nested case-control study. Br Med J 2002; 325: 243-247.
7. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (Suppl. 1): 7-14.
8. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
9. Sernyak M, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-566.
10. Hsu DJ, Ghaemi SN, Thase ME, Wisniewski SR, Sachs GS. Pharmacological treatment of bipolar disorder: Psychotropic medication use in the first 500 patients in the Systematic Treatment Enhancement Program for Bipolar Disorder. Bipolar Disord 2003; 5 (Suppl. 1): 24.
11. The Diabetes Control and Complications Trial (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 877-886.
12. Ross SA, Zinman B, Campos RV, Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001; 24: 292-298.
13. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-1784.
14. Garg S, Anderson H, Gerard L et al. Impact of insulin lispro on HbA1c values in insulin pump users. Diabetes Obes Metab 2000; 2: 307-311.
15. Motheral BR, Fairman KA. The use of claims databases for outcomes research: Rationale, challenges and strategies. Clin Ther 1997; 19: 346-366.
16. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-1420.
17. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care 1999; 26: 771-789.
18. Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001; 13: 103-113.
19. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003; 48: 458-461.